Literature DB >> 22160187

Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells.

Rong-Xin Chen1, Yun-Hong Xia, Tong-Chun Xue, Sheng-Long Ye.   

Abstract

MicroRNA-96 (miR-96) expression is dysregulated in certain types of cancers. However, the role of miR-96 in hepatocellular carcinoma (HCC) invasion and metastasis remains elusive. miR-96 expression was investigated in a number of HCC cell lines by quantitative reverse transcription‑polymerase chain reaction (RT-PCR). Cell invasive ability of metastatic HCCLM6 cells transfected with anti-miR-96 oligonucleotides or miR-96 mimic was determined by Matrigel invasion assay in vitro. In addition, metastasis-associated protein, osteopontin, was evaluated by Western blotting. miR-96 expression was significantly increased in highly metastatic HCCLM6 cells. Decreasing miR-96 expression with anti-miR-96 oligonucleotides led to reduced migration and invasion of HCCLM6 cells in vitro. In particular, down-regulation of miR-96 decreased osteopontin expression in HCCLM6 cells. Suppression of miR-96 expression inhibits the invasion of HCC cells, suggesting that miR-96 may be a therapeutic target for inhibiting HCC invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160187     DOI: 10.3892/mmr.2011.695

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  18 in total

1.  Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1.

Authors:  Guanghua Liu; Xin Zhao; Jingmin Zhou; Xiangming Cheng; Zixing Ye; Zhigang Ji
Journal:  Cancer Biol Ther       Date:  2018-11-21       Impact factor: 4.742

2.  MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1.

Authors:  Chunhui Lang; Miao Xu; Ziyi Zhao; Jinyao Chen; Lishi Zhang
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

Review 3.  MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine.

Authors:  Iván Lyra-González; Laura E Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  World J Hepatol       Date:  2015-06-18

4.  MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells.

Authors:  Haizhou Guo; Qianping Li; Weihao Li; Tianliang Zheng; Song Zhao; Zhangsuo Liu
Journal:  Mol Cell Biochem       Date:  2014-01-29       Impact factor: 3.396

Review 5.  SUMO and ischemic tolerance.

Authors:  Yang-ja Lee; John M Hallenbeck
Journal:  Neuromolecular Med       Date:  2013-06-18       Impact factor: 3.843

6.  Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

Authors:  Yueming Chen; Xueyan Dong; Daojun Yu; Xianjun Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

7.  Down-regulation of miR-96 by bone morphogenetic protein signaling is critical for vascular smooth muscle cell phenotype modulation.

Authors:  Sunghwan Kim; Akiko Hata; Hara Kang
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

Review 8.  Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma.

Authors:  Min Yao; Li Wang; Yao Yao; Hong-Bing Gu; Deng-Fu Yao
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

9.  Global protein conjugation by ubiquitin-like-modifiers during ischemic stress is regulated by microRNAs and confers robust tolerance to ischemia.

Authors:  Yang-ja Lee; Kory R Johnson; John M Hallenbeck
Journal:  PLoS One       Date:  2012-10-18       Impact factor: 3.240

10.  Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96.

Authors:  Kiren Ubhi; Edward Rockenstein; Christine Kragh; Chandra Inglis; Brian Spencer; Sarah Michael; Michael Mante; Anthony Adame; Douglas Galasko; Eliezer Masliah
Journal:  Eur J Neurosci       Date:  2013-12-05       Impact factor: 3.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.